Role of osteogenic Dickkopf-1 in bone remodeling and bone healing in mice with type I diabetes mellitus

Nick Hildebrandt,Lorenz C Hofbauer,Martina Rauner,Juliane Salbach-Hirsch,Sylvia Thiele,Juliane Colditz,Paula Goes,Caio Dutra

doi:10.1038/s41598-021-81543-7

Nick Hildebrandt, Lorenz C Hofbauer + Show 6 more

Open Access

https://doi.org/10.1038/s41598-021-81543-7

Copy DOI

Abstract

Type 1 diabetes mellitus (T1DM) is associated with low bone mass and a higher risk for fractures. Dickkopf-1 (Dkk1), which inhibits Wnt signaling, osteoblast function, and bone formation, has been found to be increased in the serum of patients with T1DM. Here, we investigated the functional role of Dkk1 in T1DM-induced bone loss in mice. T1DM was induced in 10-week-old male mice with Dkk1-deficiency in late osteoblasts/osteocytes (Dkk1f/f;Dmp1-Cre, cKO) and littermate control mice by 5 subsequent injections of streptozotocin (40 mg/kg). Age-matched, non-diabetic control groups received citrate buffer instead. At week 12, calvarial defects were created in subgroups of each cohort. After a total of 16 weeks, weight, fat, the femoral bone phenotype and the area of the bone defect were analyzed using µCT and dynamic histomorphometry. During the experiment, diabetic WT and cKO mice did not gain body weight compared to control mice. Further they lost their perigonadal and subcutaneous fat pads. Diabetic mice had highly elevated serum glucose levels and impaired glucose tolerance, regardless of their Dkk1 levels. T1DM led to a 36% decrease in trabecular bone volume in Cre− negative control animals, whereas Dkk1 cKO mice only lost 16%. Of note, Dkk1 cKO mice were completely protected from T1DM-induced cortical bone loss. T1DM suppressed the bone formation rate, the number of osteoblasts at trabecular bone, serum levels of P1NP and bone defect healing in both, Dkk1-deficient and sufficient, mice. This may be explained by increased serum sclerostin levels in both genotypes and the strict dependence on bone formation for bone defect healing. In contrast, the number of osteoclasts and TRACP 5b serum levels only increased in diabetic control mice, but not in Dkk1 cKO mice. In summary, Dkk1 derived from osteogenic cells does not influence the development of T1DM but plays a crucial role in T1DM-induced bone loss in male mice by regulating osteoclast numbers.

Highlights

1 (IGF-1), and the reduced concentration of insulin itself and thereby the lack of anabolic effects on bone provided by the peptide h ormone[9,10]
The level of the advanced glycation end products (AGEs) is elevated, which is known to interfere with osteoblast attachment to bone matrix and to induce apoptosis in mesenchymal stem cells (MSC), thereby compromising osteoblastogenesis and subsequently osteoblast activity[11,12]
Our results show that mice lacking Dkk[1] in osteoblasts and osteocytes are not fully protected from trabecular bone loss due to Type 1 diabetes mellitus (T1DM), but that they lose less bone than their wildtype littermates

Summary

Introduction

1 (IGF-1), and the reduced concentration of insulin itself and thereby the lack of anabolic effects on bone provided by the peptide h ormone[9,10]. Mechanosensing by osteocytes is reduced in diabetic mice, which may negatively impact on the regulation of the bone remodeling cycle[14]. The Wnt signaling pathway is one of the most important pathways to regulate bone mass. It stimulates bone formation via osteoblasts and reduces osteoclastogenesis, thereby, reducing bone r esorption[15,16]. Bone mass regulation via Dkk[1] is not dependent on systemic levels, but on local Dkk[1] expression, secreted by osteoblasts and osteocytes[23]. We assessed here if skeletal Dkk[1] production is implicated in the pathogenesis of T1DM-induced bone loss. The effects of Dkk[1] in diabetic bone disease appear to be sitespecific and depending on modeling vs. remodeling activities

Objectives

Methods

Results

Conclusion